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 INTRODUCTION
Taking advantage of this year’s synergy, as World 
Kidney Day (WKD) and International Women’s Day fall 
on the same day, the theme chosen for WKD 2018 was 
“Kidneys and Women’s health”, drawing the attention 
of the nephrology community to the special features 
of diseases of the kidney as they affect women. When 
focusing on this subject, we come to see the major 
gaps in this area of knowledge. On one hand, it is now 
comprehensively accepted that there are unique bio-
logical and behavioral differences resulting in sex/gen-
der variances, albeit mostly in favour of women. How-
ever, on the other, despite mounting evidence in 
multiple medical disciplines, these disparities have not 
been so well explored in nephrology, and so we try, in 
this editorial, to review current knowledge n this field.
 EPIDEMIOLOGY
Acknowledgment of chronic kidney disease (CKD) 
and its dimension as a public health problem has gained 
greater importance in the last two decades, due to the 
recognition of CKD’s high morbimortality and high 
prevalence, ranging from 10-13%1. As for gender dif-
ferences in CKD epidemiology, it seems that the propor-
tion of women with CKD is higher than that of men, 
resulting in a 60:40 ratio, whereas in some countries 
including Portugal, it becomes even more unbalanced 
with a twofold higher ratio of CKD in women than in 
men2. This disparity may not accurately denote a higher 
CKD burden, as it most likely results from a longer life 
expectancy of women and possibly from a CKD over-
diagnosis due to inherent limitations of estimated glo-
merular filtration rate equations, including lack of cor-
rection for body surface area. Hence, when considering 
CKD progression, most data from population -based 
studies show that men have a faster function decline 
than women. Many theories based on biological dif-
ferences such as the protective effects of estrogens 
versus the detrimental effects of testosterone or socio-
cultural lifestyle disparities have been postulated; how-
ever, clinical evidence to support these is rather weak.
Regarding end -stage renal disease (ESRD) and starting 
renal replacement therapy (RRT), we observe a male 
predominance1, in a proportion of 60:40, which, although 
surprisingly consistent globally, there are still few data 
to compare the gender difference for the treatment gaps. 
Although when considering faster CKD progression in 
men, one must recognize non -biological factors, such as 
access to medical care and personal preference such as 
greater choice for conservative care among elderly wom-
en. Nevertheless, mortality is higher among men at all 
levels of predialysis CKD, and, even so, they reach ESRD 
in a higher proportion than women. Mortality among 
individuals on RRT is similar for men and women1.
Another unique to women event, pregnancy poses 
unparalleled obstacles for women as a cause of acute 
kidney injury in women of childbearing age. Ranging, 
in developed countries, from hypertensive complica-
tions (such as preeclampsia) or other thrombotic micro-
angiopathies to other obstetric complications (including 
septic abortions, placental abruption, and intravascular 
disseminated coagulation) more common in developing 
countries. All of which may lead to subsequent CKD, 
but quantification of this risk is not known.
Turning to access to transplantation, the perception 
that this is lower for women than for men dates back 
more than three decades. This may be due to patient 
preference, gender selection bias by health -care person-
nel, or socioeconomic reasons. However recent studies 
based on developed countries evidenced declining dispari-
ties, after adjusting the analysis of transplantation rates 
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in men and women for the preformed antibodies. The 
sensitizing event developed during pregnancy leads to 
women having more preformed antibodies, which justifies 
14% fewer deceased kidney allocation in women1. In 
terms of living donation, apart from the predictable dis-
advantage of preformed antibodies, particularly in spousal 
donations, the differences remain mostly speculative.
  WOMEN’S SPECIFICITIES: 
PREGNANCY IN CKD, DIALYSIS  
AND TRANSPLANTATION
Where do women with CKD stand in terms of preg-
nancy? CKD affects up to 6% of women of childbearing 
age in high -income countries, and is estimated to affect 
3% of pregnant women3. The complex alterations of the 
hypothalamic -pituitary -ovarian axis together with the 
effects of inflammatory disease are the major reasons 
for compromised fertility in women with CKD. Neverthe-
less, the chance of pregnancy is high enough so that in 
daily practice one needs to prevent it if it is not desired 
or approach it in a multidisciplinary manner if it does 
occur. The perception of the intimate association 
between kidney disease and pregnancy reflects the 
adverse outcomes from early stages of CKD until later 
stages of kidney function during pregnancy and post-
partum. Lindheimer et al demonstrated that women 
presenting pre ‑pregnancy serum creatinine ≥2.8mg/dL 
were associated to pregnancy problems in about 86% 
and only 76% had successful obstetric outcomes. Forty 
percent of these women progressed to ESDR within 1 
year3. Notably, baseline hypertension and proteinuria 
are the most important modulators of pregnancy -related 
risks. While not all causes of kidney disease are major 
determinants of worsening of kidney disease during 
pregnancy, diabetic nephropathy and lupus nephritis 
have been linked to more adverse outcomes. Equally so, 
the negative effect of kidney disease on pregnancy can 
be shown by extremely high rates of caesarean section 
(70%), preterm delivery <37 (89%) and <34 (44%) weeks, 
small gestational age <10% (50%) and <5% (25%) per-
centiles as well as increased needs for neonatal intensive 
care unit (70%)4. Pregnancy per se is a potential time-
frame for the initial diagnosis of CKD and kidney biopsy 
seems no longer frightening when prompt diagnosis is 
required, as long as it is performed with controlled blood 
pressure, normal coagulation and under 30 to 32 weeks’ 
pregnancy4. Fortunately, CKD and pregnancy are no 
longer enemies for women who desire to conceive. While 
we believe that small impairments of kidney function 
are linked to successful pregnancies, we agree that baby 
steps should be taken when counseling a pregnant 
woman with a more advanced CKD, in terms of managing 
determined health issues (Table I).
For countless years, being on dialysis and getting preg-
nant was considered unthinkable among medical com-
munity. However, in the last few decades, great progress 
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Table I




•  Recommend fertility preservation if cyclophosphamide 
needed
•  Use progesterone -only contraception methods
•  Provide folic acid supplementation (5mg/day)
•  Remove teratogens before conception (including statins)
•  Use ACE inhibitors and ARB until conception
•  Retinopathy assessment and target HbA1c% <6,5% in 
diabetic nephropathy
Lupus nephritis
•  Recommend lupus inactivity for 6 months
•  Low -molecular -weight -heparin in proteinuric, lupus flare 
and antiphospholipid antibodies
•  Hydroxychloroquine to reduce the risk of congenital 
heart block
Diabetes Mellitus
•  Screening of gestational DM when using steroids and/
or calcineurin inhibitors
•  Switch to insulin if type 2 diabetes
Hypertension
•  Target BP<140 -90mmHg
•  Use labetalol, nifedipine and methyldopa
Preeclampsia
•  Low dose aspirin 75 -100mg/day
Postpartum
•  Restart RAAS blockage as soon as renal function is stable 
(enalapril, captopril safe to use in breastfeeding)
Hemodialysis •  Target diastolic BP 80 -90mmHg
•  Avoid diuretics, ACE inhibitors and ARB
•  Intensify dialysis: 5 -7 per week; >20 hours/week; urea 
<107mg/dL; increase dry weight 0.45 -1kg/week in first 
trimester; 0.3 -0,5kg/week in the second and third tri-
mester
•  Minimum heparin use
•  Improvement of calcium/phosphorus metabolism
•  Anaemia: Hb target 10 -11g/dL; serum ferritin 200 -300 
μg/mL. Iron supplementation 10 ‑15mg/day + 50 ‑100% 
increase EPO
•  Nutrition: calories intake of 25 -35Kcal/Kg/day
Peritoneal 
Dialysis 
•  Increase exchanges
•  No indication to switch to HD, if dialysis dose achieved.
Kidney 
Transplantation
•  Conceive at least 1 year post -transplantation and ide-
ally with:
•  No rejection in previous year
•  Stable renal function
•  Minimal proteinuria
•  Stable non teratogenic medication: tacrolimus, azathio-
prine and steroids; Avoid mycophenolate and cyclospo-
rine
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has been made in the care of pregnant dialysis patients 
(and even in pre -pregnancy stages). These results have 
been linked to increased dialysis intensity during preg-
nancy and expanded multidisciplinary care. In fact, since 
the first successful pregnancy in a patient on hemodialysis 
(HD) in 1971, the number of successful pregnancies have 
been increasing over time with a fetal survival gain of 
~25% per decade, reaching over 90% in recent years5. 
Presently, women who desire to get pregnant are no 
longer dissuaded from conceiving while on dialysis if there 
is no forthcoming option for transplantation. Still, aware-
ness of the potential risks must be a mainstay, as even 
intensively dialyzed women present high rates of preec-
lampsia (18%) and cervical incompetence (18%), higher 
than those expected for the general population. Consid-
ering the use of the abdominal cavity in peritoneal dialysis 
(PD) patients, it would seem unreasonable to maintain 
the pregnant patients in PD. Surprisingly, PD can be con-
tinued during pregnancy as long as an increase in the 
number of exchanges is performed. It should be noted 
however that a total dialysis dose may not be achieved 
and this may be linked to decreased overall surface of 
exchange due to a gravid uterus. As far as fetal outcomes 
are concerned, a higher rate of low -weight newborns can 
be expected (67% in PD versus 31% in HD)6.
Renal transplantation is the desire of most ESRD 
patients. It has advantages, particularly for women who 
desire to conceive, as fertility is usually restored in wom-
en following transplantation. The first successful preg-
nancy in a renal transplant recipient occurred in 1958, 
with an exponential rise in the number of pregnancies 
over the subsequent decades. Nonetheless, an inferior 
rate exists when compared to the general population3. 
As far as optimal post -transplantation pregnancy timing 
goes, there are various unanswered questions. The first 
concerns optimal pre -pregnancy kidney function and 
the second the interplay of the effects of immunosup-
pressive therapy on both pregnancy and allograft out-
comes. When assessing reduced pregnancy rates in 
transplanted women, a significant bias may exist con-
cerning improved contraception counseling in this popu-
lation as well as the employment of teratogenic medica-
tion such as first -line agent mycophenolate mofetil.
  WOMEN: KIDNEY AND AUTOIMMUNE 
DISEASES
When it comes to autoimmune diseases and their 
known predominance in females, isn’t it time to reform 
diagnostic and treatment options in this specific 
population? Autoimmune diseases such as systemic 
lupus erythematosus (SLE), rheumatoid arthritis (RA) 
and systemic scleroderma (SS) play a leading role in 
public health issues as important causes of morbidity 
and mortality among women. SLE predominantly affects 
women of childbearing age (9:1 female -to -male ratio 
with up to 15:1 in peak reproductive years), and lupus 
nephritis in particular occurs in ~40% of cases6. Unfor-
tunately, even today, in the context of preserved kidney 
function, the risk of adverse pregnancy outcomes is 
increased in women with active lupus nephritis. While 
black and Hispanic ethnicity are non -modifiable risk 
factors for poor pregnancy outcomes (mostly preterm 
delivery), proteinuria, hypertension and active disease 
are all factors that can be managed from a medical per-
spective through effective preconception management. 
Fortunately, the new millennium has brought us new 
strategies. Tacrolimus is now seen as a new hope when 
lupus flare develops3, avoiding premature rupture of 
membranes, preterm delivery, maternal sepsis, and 
gestational diabetes related to steroid therapy. Similarly, 
RA also affects predominantly women (4:1 female -to-
-male ratio with a peak incidence between 45 and 55 
years old), though, unlike SLE, pregnancy leads to a 
surprising improvement of the disease. Although SS is 
reported in a not so pronounced female to male ratio 
(3:1 to 14:1 with a peak incidence in the fifth and sixth 
decades) it is additionally linked to the female popula-
tion. An equal denominator, estrogens7 are part of the 
pathophysiology of all these 3 diseases previously 
described, affecting either positively or negatively the 
disease. With this in mind, where are we heading to in 
the new paradigm of estrogen therapies?
 CONCLUSION
Women have unique risks for kidney diseases. As in 
many other areas of scientific knowledge, particular 
aspects of female kidney disease remain uncharted ter-
ritory. There are notable signs of improved management 
in this field but further efforts should be made in order 
to achieve full potential outcomes. Turning back to 1975, 
we found in The Lancet opinion: “Children of women with 
renal disease used to be born dangerously or not at all 
– not at all if their doctors had their way”8. In the new 
millennium, we urge the need of fully changing this para-
digm, as children of women with renal disease should be 
well born whilst their mothers are assisted by new mil-
lennium doctors aiming for new millennium outcomes.
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